Fig. 2From: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionProgression-Free Survival in months for patients treated with IL-2 alone or IL-2 following PD-1 inhibition in metastatic melanoma (a) and metastatic renal cell carcinoma (b)Back to article page